New Approvals In Spotlight As China Gears For National Congress
Proposed Biosecurity Law Also Gains Momentum
Executive Summary
In a sign that attention in China may be shifting back to more routine regulatory work as the local coronavirus outbreak appears to recede, authorities have granted approvals to multiple new drugs for cancer and rare diseases, as the government gears up to hold its delayed annual congress in Beijing.
You may also be interested in...
Tech Transfer Roundup: Inside The Law That Transformed The Research Landscape
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
Ready, Set, Go: China To Use Patient-Reported Outcomes In Clinical Studies
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.
Biotech Picks Up Pace In China While Investors Project Hong Kong Confidence
Beneath booming healthcare financing and deal-making in Asia is a constant flow of ready capital, but there are also challenges that may present hurdles to Hong Kong overtaking Nasdaq as the premier site for listings in the sector, a recent summit heard.